BRPI0413426A - antagonistas de receptor novo - Google Patents

antagonistas de receptor novo

Info

Publication number
BRPI0413426A
BRPI0413426A BRPI0413426-5A BRPI0413426A BRPI0413426A BR PI0413426 A BRPI0413426 A BR PI0413426A BR PI0413426 A BRPI0413426 A BR PI0413426A BR PI0413426 A BRPI0413426 A BR PI0413426A
Authority
BR
Brazil
Prior art keywords
receptor antagonists
nogo
new receptor
nucleic acids
antigen binding
Prior art date
Application number
BRPI0413426-5A
Other languages
English (en)
Inventor
Daniel H S Lee
R Blake Pepinsky
Weiwei Li
Sylvia A Rabacchi
Jane K Relton
Dane S Worley
Stephen M Strittmatter
Dinah Y W Sah
Original Assignee
Biogen Idec Inc
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2003/025004 external-priority patent/WO2004014311A2/en
Application filed by Biogen Idec Inc, Univ Yale filed Critical Biogen Idec Inc
Publication of BRPI0413426A publication Critical patent/BRPI0413426A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)

Abstract

"ANTAGONISTAS DE RECEPTOR NOVO". São descritos polipeptídeos de receptor-1 de Nogo imunogênicos, anticorpos de receptor 1 de Nogo, fragmentos de ligação de antígeno destes, receptores de Nogo solúveis e proteínas de fusão destes e ácidos nucléicos codificando o mesmo. São também descritas composições que compreendem, e métodos para preparar e usar tais anticorpos de receptor de Nogo, fragmentos de ligação de antígeno destes, receptores de Nogo solúveis, e proteínas de fusão destes e ácidos nucléicos codificando os mesmos.
BRPI0413426-5A 2003-08-07 2004-01-30 antagonistas de receptor novo BRPI0413426A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2003/025004 WO2004014311A2 (en) 2002-08-10 2003-08-07 Nogo receptor antagonists
PCT/US2004/002702 WO2005016955A2 (en) 2003-08-07 2004-01-30 Nogo receptor antagonists

Publications (1)

Publication Number Publication Date
BRPI0413426A true BRPI0413426A (pt) 2006-10-17

Family

ID=34192565

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413426-5A BRPI0413426A (pt) 2003-08-07 2004-01-30 antagonistas de receptor novo

Country Status (11)

Country Link
EP (1) EP1660517A4 (pt)
JP (1) JP2007501612A (pt)
CN (1) CN1926147A (pt)
AU (1) AU2004264405A1 (pt)
BR (1) BRPI0413426A (pt)
CA (1) CA2535007A1 (pt)
IS (1) IS8339A (pt)
MX (1) MXPA06001444A (pt)
NO (1) NO20061081L (pt)
PL (1) PL380274A1 (pt)
WO (1) WO2005016955A2 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119165B2 (en) 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
CA2495121A1 (en) 2002-08-10 2004-02-19 Yale University Nogo receptor antagonists
ES2215469B1 (es) 2002-09-30 2005-12-16 Bsh Electrodomesticos España, S.A. Aparato de aire acondicionado.
ES2215470B1 (es) 2002-09-30 2005-12-16 Bsh Electrodomesticos España, S.A. Aparato de aire acondicionado.
PL2248899T3 (pl) 2003-03-19 2015-10-30 Biogen Ma Inc Białko wiążące receptor nogo
KR101239542B1 (ko) 2004-06-24 2013-03-07 바이오겐 아이덱 엠에이 인코포레이티드 탈수초화를 수반하는 병의 치료
WO2006017673A2 (en) 2004-08-03 2006-02-16 Biogen Idec Ma Inc. Taj in neuronal function
WO2006124627A2 (en) * 2005-05-12 2006-11-23 Biogen Idec Ma Inc. Methods of treating conditions involving neuronal degeneration
WO2007008732A2 (en) 2005-07-07 2007-01-18 Yale University Compositions and methods for suppressing axonal growth inhibition
CA2902070A1 (en) 2005-07-08 2007-01-18 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
CN101277974A (zh) 2005-09-30 2008-10-01 阿伯特有限及两合公司 排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
CA2640423C (en) 2006-01-27 2016-03-15 Biogen Idec Ma Inc. Nogo receptor antagonists
WO2008013782A2 (en) 2006-07-24 2008-01-31 Biogen Idec Ma Inc. Methods for promoting myelination, neuronal survival and oligodendrocyte differentiation via administration of sp35 or trka antagonists
EP2081562B1 (en) 2006-09-20 2016-02-24 The Board of Regents of The University of Texas System Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief
JP5653622B2 (ja) * 2006-11-21 2015-01-14 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ Ｎｏｇｏ−６６受容体（ＮＧＲ）に対する中和モノクローナル抗体及びその使用
WO2009094459A1 (en) 2008-01-22 2009-07-30 The Board Of Regents Of The University Of Texas System Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
JP2011527572A (ja) 2008-07-09 2011-11-04 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｌｉｎｇｏ抗体または断片を含む組成物
KR20120118002A (ko) 2009-12-08 2012-10-25 애보트 게엠베하 운트 콤파니 카게 망막 신경 섬유 층 변성의 치료에 사용하기 위한 ｒｇｍ ａ 단백질에 대한 모노클로날 항체
EP3369746A1 (en) 2012-01-27 2018-09-05 AbbVie Deutschland GmbH & Co KG Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
MX381731B (es) 2012-05-14 2025-03-13 Biogen Ma Inc Antagonistas de proteina que interactua con el receptor nogo 2 que contiene repeticion rica en leucina y dominio de inmunoglobulina (lingo-2) para el tratamiento de afecciones que involucran neuronas motoras.
JP2018504400A (ja) 2015-01-08 2018-02-15 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用
CN110488007A (zh) * 2019-09-26 2019-11-22 天津华科泰生物技术有限公司 一种快速检测神经胶质纤维酸性蛋白的免疫层析检测卡及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4682999A (en) * 1998-06-16 2000-01-05 Human Genome Sciences, Inc. 94 human secreted proteins
US20050221420A1 (en) * 2001-10-22 2005-10-06 Carmen Barske Nogo receptor homologues and their use

Also Published As

Publication number Publication date
CA2535007A1 (en) 2005-02-24
EP1660517A4 (en) 2006-10-04
MXPA06001444A (es) 2006-05-15
NO20061081L (no) 2006-04-18
WO2005016955A3 (en) 2006-07-20
PL380274A1 (pl) 2007-01-22
AU2004264405A1 (en) 2005-02-24
JP2007501612A (ja) 2007-02-01
EP1660517A2 (en) 2006-05-31
IS8339A (is) 2006-03-07
WO2005016955A2 (en) 2005-02-24
CN1926147A (zh) 2007-03-07

Similar Documents

Publication Publication Date Title
DK1534736T3 (da) Nogo-receptorantagonister
IS8339A (is) Mótlyf viðtaka NOGO
CY1111097T1 (el) Πρωτεϊνη δεσμευσης του υποδοχεα nogo
EP2526968A3 (en) Nogo receptor antagonists
YU19903A (sh) Novi receptor nukleinskih kiselina i polipeptida
AU6135101A (en) Mammalian receptor proteins; related reagents and methods
WO2002068646A3 (en) Mammalian cytokines; receptors; related reagents and methods
EP1433792A3 (en) Human receptor proteins, related reagents and methods
EA200600376A1 (ru) Антагонисты nogo-рецептора
WO2001025432A3 (en) Histamine receptor
DE60236643D1 (de) Opiatrezeptoren
WO2003087331A3 (en) Polyvalent cation-sensing receptor in atlantic salmon

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 6A E 7A ANUIDADE(S)

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.